目的探讨医用粘胶相关性皮肤损伤(medical adhesive related skin injury,MARSI)在PICC肿瘤患者中的发生情况及影响因素,为降低医用粘胶相关性皮肤损伤的发生提供护理依据。方法采用前瞻性队列研究的方法,选取2018年4月1日—11月20日在...目的探讨医用粘胶相关性皮肤损伤(medical adhesive related skin injury,MARSI)在PICC肿瘤患者中的发生情况及影响因素,为降低医用粘胶相关性皮肤损伤的发生提供护理依据。方法采用前瞻性队列研究的方法,选取2018年4月1日—11月20日在天津市某三级甲等医院行PICC置管的396例肿瘤患者作为研究对象,调查医用粘胶相关性皮肤损伤的发生率,并分析医用粘胶相关性皮肤损伤类型、医用粘胶相关性皮肤损伤发生部位及影响因素。结果肿瘤患者医用粘胶相关性皮肤损伤发生率为26.8%(106/396);医用粘胶相关性皮肤损伤类型以接触性皮炎13.9%(55/396)以及机械性皮肤损伤中的张力性损伤/水疱6.3%(25/396)为主,其次为潮湿相关性皮肤损伤1.3%(5/396),毛囊炎1.0%(4/396)。医用粘胶相关性皮肤损伤多发生在贴膜下皮肤63.2%(67/106)。多因素Logistic回归分析发现PICC导管相关感染(P<0.001,OR=3.271,95%CI:1.697~6.306)、穿刺次数(P=0.018,OR=2.474,95%CI:1.171~5.226)、导管维护周期延迟(P=0.018,OR=2.537,95%CI:1.176~5.473)是肿瘤PICC患者发生医用粘胶相关性皮肤损伤的危险因素。结论肿瘤患者PICC置管部位医用粘胶相关性皮肤损伤发生率较高,且好发于贴膜下皮肤;医用粘胶相关性皮肤损伤类型以接触性皮炎和机械性皮肤损伤居多;而感染、穿刺次数、导管维护周期延迟是医用粘胶相关性皮肤损伤发生的危险因素。展开更多
Background： Despite the rapid growth in the incidence of acute myocardial infarction （AMI） in China, there is limited information about patients＇ experiences after AMI hospitalization, especially on long-tern1 adv...Background： Despite the rapid growth in the incidence of acute myocardial infarction （AMI） in China, there is limited information about patients＇ experiences after AMI hospitalization, especially on long-tern1 adverse events and patient-reported outcomes （PROs）. Methods： The China Patient-centered Evaluative Assessment of Cardiac Events （PEACE）-Prospective AMI Study will enroll 4000 consecutive AM I patients from 53 diverse hospitals across China and follow them longitudinally for 12 months to docunlent their treatment, recovery, and outcomes. Details of patients＇ medical history, treatment, and in-hospital outcomes are abstracted from medical charts. Comprehensive baseline interviews are being conducted to characterize patient demographics, risk factors, presentation, and healthcare utilization. As part of these interviews, validated instruments are administered to measure PROs, including quality of life, symptoms, mood, cognition, and sexual activity. Follow-up interviews, measuring PROs, medication adherence, risk factor control, and collecting hospitalization events are conducted at 1, 6, and 12 months after discharge. Supporting documents for potential outcomes are collected for adjudication by clinicians at the National Coordinating Center. Blood and urine samples are also obtained at baseline, 1 - and 12-month follow-up. In addition, we are conducting a survey of participating hospitals to characterize their organizational characteristics. Conclusion： The China PEACE-Prospective AMI study will be uniquely positioned to generate new information regarding patient＇s experiences and outcomes alter AMI in China and seiwe as a foundation for quality improveinent activities.展开更多
文摘目的探讨医用粘胶相关性皮肤损伤(medical adhesive related skin injury,MARSI)在PICC肿瘤患者中的发生情况及影响因素,为降低医用粘胶相关性皮肤损伤的发生提供护理依据。方法采用前瞻性队列研究的方法,选取2018年4月1日—11月20日在天津市某三级甲等医院行PICC置管的396例肿瘤患者作为研究对象,调查医用粘胶相关性皮肤损伤的发生率,并分析医用粘胶相关性皮肤损伤类型、医用粘胶相关性皮肤损伤发生部位及影响因素。结果肿瘤患者医用粘胶相关性皮肤损伤发生率为26.8%(106/396);医用粘胶相关性皮肤损伤类型以接触性皮炎13.9%(55/396)以及机械性皮肤损伤中的张力性损伤/水疱6.3%(25/396)为主,其次为潮湿相关性皮肤损伤1.3%(5/396),毛囊炎1.0%(4/396)。医用粘胶相关性皮肤损伤多发生在贴膜下皮肤63.2%(67/106)。多因素Logistic回归分析发现PICC导管相关感染(P<0.001,OR=3.271,95%CI:1.697~6.306)、穿刺次数(P=0.018,OR=2.474,95%CI:1.171~5.226)、导管维护周期延迟(P=0.018,OR=2.537,95%CI:1.176~5.473)是肿瘤PICC患者发生医用粘胶相关性皮肤损伤的危险因素。结论肿瘤患者PICC置管部位医用粘胶相关性皮肤损伤发生率较高,且好发于贴膜下皮肤;医用粘胶相关性皮肤损伤类型以接触性皮炎和机械性皮肤损伤居多;而感染、穿刺次数、导管维护周期延迟是医用粘胶相关性皮肤损伤发生的危险因素。
文摘Background： Despite the rapid growth in the incidence of acute myocardial infarction （AMI） in China, there is limited information about patients＇ experiences after AMI hospitalization, especially on long-tern1 adverse events and patient-reported outcomes （PROs）. Methods： The China Patient-centered Evaluative Assessment of Cardiac Events （PEACE）-Prospective AMI Study will enroll 4000 consecutive AM I patients from 53 diverse hospitals across China and follow them longitudinally for 12 months to docunlent their treatment, recovery, and outcomes. Details of patients＇ medical history, treatment, and in-hospital outcomes are abstracted from medical charts. Comprehensive baseline interviews are being conducted to characterize patient demographics, risk factors, presentation, and healthcare utilization. As part of these interviews, validated instruments are administered to measure PROs, including quality of life, symptoms, mood, cognition, and sexual activity. Follow-up interviews, measuring PROs, medication adherence, risk factor control, and collecting hospitalization events are conducted at 1, 6, and 12 months after discharge. Supporting documents for potential outcomes are collected for adjudication by clinicians at the National Coordinating Center. Blood and urine samples are also obtained at baseline, 1 - and 12-month follow-up. In addition, we are conducting a survey of participating hospitals to characterize their organizational characteristics. Conclusion： The China PEACE-Prospective AMI study will be uniquely positioned to generate new information regarding patient＇s experiences and outcomes alter AMI in China and seiwe as a foundation for quality improveinent activities.
